American development bank U.S. International Development Finance Corporation (DFC) and Citi Risk Management Solution on Wednesday jointly announced a risk management solution to help Gavi to mitigate risk and overcome financial hurdles with governments that are funding COVID-19 vaccine purchases through the COVAX Facility.
At the US COVID-19 Summit, the risk management team stated that the collective and global action will be required to address and end the COVID-19 pandemic. DFC financing for vaccine-related efforts of nearly USD600m was committed during the Biden Administration.
Through the DFC support, Gavi will pre-purchase up to 2bn vaccines directly from manufacturers and allocate these vaccines rapidly and equitably throughout the world. DFC's financing will offer protection against political risks in nine self-financing countries across Latin and Central America, the Middle East and Eastern Europe, participating in COVAX, covering more than USD383m in insurance.
Co-led by Gavi, the Coalition for Epidemic Preparedness Innovations (CEPI) and the World Health Organization (WHO), COVAX aims to provide fair and equitable access to COVID-19 vaccines for every country in the world.
COVAX, the vaccines pillar of the Access to COVID-19 Tools (ACT) Accelerator, is co-led by CEPI, Gavi and WHO – working in partnership with UNICEF and PAHO as delivery partners, developed and developing country vaccine manufacturers, the World Bank and others.
Pfizer reports positive Phase 3 data for ABRYSVO in adults at risk for RSV disease
Clover Bio announces SCB-1019 vaccine candidate Phase I trial data in initial young adult cohort
Sanofi launches Verorab for rabies prophylaxis in UK
BioVaxys expands patent portfolio for DPX delivery platform and advances DPX SurMAGE
YS Biopharma repays USD40m loan facility
Kintara Therapeutics and TuHURA Biosciences to merge
VGXI names new chief accounting officer
Moderna reports positive interim results from next-generation COVID-19 vaccine trial
Valneva launches Phase 1 trial for next-generation Zika vaccine
Circio Holding ASA confirms licensing deal with IOVaxis Therapeutics in China and Singapore
Everest Medicines names new chief medical officer and chief product officer
Pfizer's PREVENAR 20 gains European Commission approval for paediatric pneumococcal vaccine